Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

PubMed  Google Scholar 

Johnston PG, Stage II. Colorectal cancer: to treat or not to treat. Oncologist. 2005;10:332–4.

Article  Google Scholar 

Al BBI, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Cutsem EV, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage ii colon cancer. J Clin Oncol. 2004;22:3408–19.

Article  Google Scholar 

Messersmith WA. Systemic management of colorectal cancer. J Natl Compr Canc Ne. 2017;15:699–702.

Article  Google Scholar 

Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54:5–16.

Article  Google Scholar 

Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol. 2017;28:958–68.

CAS  Article  Google Scholar 

Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4:343–64.

CAS  Article  Google Scholar 

Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367–86.

Article  Google Scholar 

Starr TK, Allaei R, Silverstein KAT, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O’Sullivan MG, Matise I, Dupuy AJ, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science. 2009;323:1747–50.

CAS  Article  Google Scholar 

Parsons DW, Wang TL, Samuels Y, Bardelli A. Colorectal cancer: mutations in a signalling pathway. Nature. 2005;436:792–2.

CAS  Article  Google Scholar 

Kucherlapati R, Wheeler D. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

Article  Google Scholar 

Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007;446:676–9.

CAS  Article  Google Scholar 

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.

CAS  Article  Google Scholar 

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.

CAS  Article  Google Scholar 

Hong SP, Min BS, Kim TI, Cheon JH, Kim NK, Kim H, Kim WH. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer. 2012;48:1235–43.

CAS  Article  Google Scholar 

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.

Article  Google Scholar 

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13–21.

CAS  Article  Google Scholar 

Lievre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;3:374–9.

Article  Google Scholar 

Waring P, Tie J, Maru D, Karapetis CS. RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer. Clin Colorectal Canc. 2016;15:95–103.

Article  Google Scholar 

Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC Focus Trial. J Clin Oncol. 2009;27:5931–7.

CAS  Article  Google Scholar 

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.

CAS  Article  Google Scholar 

Benson III Al B, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, et al. NCCN guidelines insights colon cancer, version 2.2018-featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2018;16:359–69.

Article  Google Scholar 

Hapfelmeier A, Ulm K. A new variable selection approach using random forests. Comput Stat Data An. 2013;60:50–69.

Article  Google Scholar 

Stephan J, Stegle O, Beyer A. A random forest approach to capture genetic effects in the presence of population structure. Nat Commun. 2015;6:7432.

CAS  Article  Google Scholar 

Siroky DS. Navigating random forests and related advances in algorithmic modeling. Statistics Surveys. 2009;3:147–63.

Article  Google Scholar 

Wang Y, Peng Z, Meng R, Tao T, Wang Q, Zhao C, Liu H, Song R, Zheng J, Qin Q, et al. NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling. Oncol Rep. 2017;38:221–8.

Article  Google Scholar 

Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, Song R, Yang X, Wang Q, Gu S, et al. Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett. 2019;453:107–21.

CAS  Article  Google Scholar 

Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, Liauw SL. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012;19:2471–6.

Article  Google Scholar 

Tarantino I, Warschkow R, Schmied BM, Güller U, Mieth M, Cerny T, Büchler MW, Ulrich A. Predictive value of CEA for survival in stage i rectal cancer: a population-based propensity score-matched analysis. J Gastrointest Surg. 2016;20:1213–22.

Article  Google Scholar 

Thomas LR, Tansey WP. proteolytic control of the oncoprotein transcription factor myc. Adv Cancer Res. 2011;110:77–106.

CAS  Article  Google Scholar 

von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, et al. The F-Box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-myc-regulated transcription. Mol Cell. 2003;11:1189–200.

Article  Google Scholar 

Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004;101:9085–90.

CAS  Article  Google Scholar 

Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32:1284–95.

CAS  Article  Google Scholar 

Elbadawy M, Usui T, Yamawaki H, Sasaki K. Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers. 2018;10:164.

Article  Google Scholar 

Elbadawy M, Usui T, Yamawaki H, Sasaki K. Emerging roles of C-Myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer. Int J Mol Sci. 2019;20:2340.

CAS  Article  Google Scholar 

Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, Hazama S, Takenouchi H, Nakajima M, Tsunedomi R, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int J Mol Sci. 2018;19:1098.

Article  Google Scholar 

Hari DM, Leung AM, Lee J, Sim M, Vuong B, Chiu CG, Bilchik AJ. AJCC cancer staging manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surgeons. 2013;217:181–90.

Article  Google Scholar 

Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, et al. Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:370–98.

Norén E, Almer S, Söderman J. Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease. BMC Gastroenterol. 2017;17:68.

Ma Q, Yang Y, Feng D, Zheng S, Meng R, Fa P, Zhao C, Liu H, Song R, Tao T, et al. MAGI3 negatively regulates Wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells. Oncotarget. 2015;6:35851–65.

Article  Google Scholar 

Qian Ma, Yan Z, Ran M, Kunming X, Ying X, Song L, Zonglin He, Tao T, Ying Y, Jizong Z, et al. MAGI3 suppresses glioma cell proliferation via upregulation of PTEN expression. Biomed Environ Sci. 2015;28:502–9.

Article  Google Scholar 

Lee SJ, Ritter SL, Zhang H, Shim H, Hall RA, Yun CC. MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology. 2011;140:924–34.

CAS  Article  Google Scholar